Synthesis and evaluation of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate analogs as competitive partial agonists of butyrophilin 3A1.

Autor: Singh R; Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, 06269-3092, United States; Department of Pharmaceutical Sciences, School of Health Sciences & Technology, Dr. Vishwanath Karad, MIT-World Peace University, Pune, 411038, India., Rani S; Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, 06269-3092, United States., Jin Y; Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, 06269-3092, United States., Hsiao CC; Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, 06269-3092, United States., Wiemer AJ; Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, 06269-3092, United States; Institute for Systems Genomics, University of Connecticut, Storrs, Connecticut, 06269-3092, United States. Electronic address: andrew.wiemer@uconn.edu.
Jazyk: angličtina
Zdroj: European journal of medicinal chemistry [Eur J Med Chem] 2024 Oct 05; Vol. 276, pp. 116673. Date of Electronic Publication: 2024 Jul 14.
DOI: 10.1016/j.ejmech.2024.116673
Abstrakt: Phosphoantigens (pAgs) induce conformational changes after binding to the intracellular region of BTN3A1 which result in its clustering with BTN2A1, forming an activating ligand for the Vγ9Vδ2 T cell receptor. Here, we designed a small panel of bulky analogs of the prototypical pAg (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) that contain an aromatic ring attached to the C-3 position in place of methyl group. These compounds bind with high affinity to BTN3A1 but fail to fully support its interaction with BTN2A1 and only partially trigger T cell activation relative to HMBPP. Furthermore, they can compete with HMBPP for cellular binding to BTN3A1 and reduce the cellular response to HMBPP, a classic partial agonist phenotype. Trifluoromethyl analog 6e was the weakest agonist but the strongest inhibitor of HMBPP ELISA response. Our study provides a rationale for the mode of action of pAg-induced γδ T cell activation and provides insights into other naturally occurring BTN proteins and their respective ligands.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Andrew Wiemer reports financial support was provided by National Institutes of Health. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: